Merit Medical Beats Q2 EPS by 24%, Lifts 2026 Guidance Above Consensus
MMSI sits 40% above its 52-week low of $59.74 on elevated volume (2.3× avg).
Summary
Merit Medical delivered a strong Q2, with adjusted EPS of $1.19 crushing the $0.96 consensus — a 24% beat. Revenue rose 10% to an undisclosed figure, driven by U.S. strength and double-digit growth in cardiac, endoscopy, and OEM segments. Management raised full-year 2026 guidance: revenue now seen at $1.631-$1.643 billion (up from $1.612-$1.634 billion) and non-GAAP EPS at $4.25-$4.35 (up from $4.01-$4.15), both above prior Street estimates. The guidance excludes potential trade policy impacts and material acquisitions. This follows a clean 2025 with double-digit growth and resolution of an SEC inquiry, reinforcing the turnaround narrative. The stock, trading at 19x forward earnings, may see multiple expansion if execution continues.
At the time of this announcement, MMSI was trading at $83.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $59.74 to $94.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.